Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1621 1622 1626 1627
This examiner grants 57% of resolved cases
Donna Michelle Nestor serves in Tech Center 1600 and Art Unit 1621. The examiner has 83 resolved cases. The allowance rate is 56.6 percent, which represents the frequency of grants for applications reaching a final resolution.
The interview lift is 44.2 percent. This 44.2 percent figure indicates that interviews correlate with an increased probability of allowance. When considering the 83 resolved cases, the 44.2 percent lift suggests that direct communication is a beneficial tactic for practitioners. The 56.6 percent baseline allowance rate is a key metric for evaluating the prosecution environment.
The median days to allowance is 1161. This 1161-day timeline reflects the duration for successful applications to reach a grant. The 1161-day figure provides a benchmark for expected pendency in Art Unit 1621. Practitioners can use this 1161-day median and the 83 resolved cases to inform their strategy and manage expectations for the timing of a final outcome.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17623060 | COMPOSITIONS AND METHODS OF TREATING LIVER CANCERS | Final Rejection | The Johns Hopkins University |
| 18029982 | MIXTURES CONTAINING CYCLOBUTRIFLURAM | Final Rejection | BASF SE |
| 18294191 | MICROBIOCIDAL PYRAZOLE DERIVATIVES | Non-Final OA | SYNGENTA CROP PROTECTION AG |
| 18577851 | CDK19-SELECTIVE INHIBITORS, AND METHODS OF USE THEREOF | Final Rejection | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY |
| 18954506 | USE OF INDOCYANINE GREEN IN ANTIBACTERIAL OR BACTERICIDAL APPLICATION | Non-Final OA | Buddhist Tzu Chi Medical Foundation |
| 17995806 | PI3 KINASE INHIBITORS AND USES THEREOF | Final Rejection | Purdue Research Foundation |
| 18596363 | TARGETED TREATMENT FOR SKIN FRAGILITY DISEASES | Non-Final OA | University of Washington |
| 18665776 | SYNTHESIS OF 2'-(7,7-dimethyl-1'H,7H-spiro[furo[3,4-b]pyridine-5,4'-piperidin]-1'-yl)-1,3-dihydro-4'H-spiro[indene-2,5'-[1,3]oxazol]-4'-one | Non-Final OA | Hoffmann-La Roche Inc. |
| 18479596 | PROCESSES FOR MAKING BICYCLIC KETONE COMPOUNDS | Final Rejection | Hoffmann-La Roche Inc. |
| 18548716 | COMPOUND AND RADIOACTIVE LABELING COMPOUND | Final Rejection | KYOTO UNIVERSITY |
| 18262053 | ARTEMISININ-PROTEASOME INHIBITOR CONJUGATES AND THEIR USE IN THE TREATMENT OF DISEASE | Final Rejection | CORNELL UNIVERSITY |
| 18953578 | IMIDAZ0[1,2-A]PYRIMIDINE-5(1 H)-ONES AS WRN INHIBITORS | Non-Final OA | Incyte Corporation |
| 17867294 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | Non-Final OA | Celgene Corporation |
| 17614826 | METHODS OF ALTERING CARDIAC REMODELING USING COMPOUNDS THAT PROMOTE GLUCOSE OXIDATION | Final Rejection | IMBRIA PHARMACEUTICALS, INC. |
| 17767018 | NOVEL HETEROARYL-TRIAZOLE COMPOUNDS AS PESTICIDES | Final Rejection | Elanco Animal Health GmbH |
| 18682647 | SULFONAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | Non-Final OA | Shanghai Hengrui Pharmaceutical Co., Ltd. |
| 17769416 | DIHYDROIMIDAZO PYRIMIDO PYRIMIDINONE COMPOUND | Final Rejection | IMPACT THERAPEUTICS (SHANGHAI), INC |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy